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Abstract
Background: Nasopharyngeal non-Hodgkin lymphomas (NNHL) are extremely rare. In this study,
we will report the progress achieved in the management of this disease in our institute.
Methods: We retrospectively reviewed the records of 26 patients having primary NNHL who
were managed between January 1997 and December 2008, to evaluate and compare their clinical
characteristics and treatment outcome. Clinical variables, including age, sex, stage, and treatment
modality, were assessed. Disease free survival and overall survival were measured. Survival curves
were constructed using the KaplanMeier method. The log-rank test was used to compare them.
Results: Median age of our patients was 52.7 years. Nasal obstruction, nasal discharge and epistaxis
were the frequent symptoms in NNHL patients. Histology of NNHL were mainly large B-cell and
follicular lymphoma. Four patients (15.4%) were at stage I, 15 (57.6%) at stage II, and 7 (27%) were
at stage III/IV. The patients were treated with chemotherapy alone (27%) or chemotherapy plus
radiotherapy (73%). At early stage (stage I/II), the patients were managed with chemo-radiotherapy.
When the whole treatment was completed, 18 patients (69.2%) achieved complete response and
remained disease free. After 25.9 months median follow-up, overall survival at 1 year was 87% and
disease free survival at 1 year was 71%. The difference in term of overall and disease free survival
between stage I, II, III and IV was significant (Log rank test: p = 0.02 for overall survival and p = 0.01
for disease free survival).
Conclusion: From our study, we conclude that histological characteristics, principle of treatment
and outcome of primary NNHL patients are particular and more studies have to be directed.
Background
Lymphomas represent the second malignant head and
neck tumours region after squamous cell carcinoma[1]. It
represents 2.5% of head and neck tumours. Oral and para-
oral regions constitute the second most affected localisa-
tions by extra nodal lymphomas after that of the gastroin-
testinal tract[2].
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NHL lymphomas are mainly diagnosed as nodal involve-
ment. However, they have the particularity to develop, in
40% of the cases, as extra nodal sites[3].
The aim of our work is to report clinical variables, histo-
logical, radiological, biological and therapeutical charac-
teristics of our patients with non hodgkin's
nasopharyngeal lymphoma at our institution. This study
aimed to compare the clinical characteristics and treat-
ment outcome in 26 patients with primary nasopharyn-
geal non hodgkin lymphoma managed in our institution
between1997 and 2008. In addition, we tried to deter-
mine the overall survival and disease free survival of our
patients.
Methods
We searched the patient records at the Department of
Clinical Oncology, national institute of oncology of
Rabat, for the period 1997-2008 for all tumours coded as
primary nasopharyngeal lymphoma. Local ethics commit-
tee of our institute has approuved this study.
The files of 26 nasopharyngeal lymphoma patients treated
at our institution were thoroughly analysed. Four were
excluded because of insufficient clinical information.
Patient's medical records were retrospectively studied:
demography, clinical stage, histological findings, treat-
ment and outcome. Radiological, pathological and surgi-
cal reports were reviewed to determine the stage of the
disease at time of histological diagnosis by using Ann
Arbor classification system. Data about treatment, notably
chemotherapy and radiotherapy were investigated. The
date of recurrence, and if applicable, the date of death
were also considered. All patients were staged according to
the Ann Arbor system [4]. The initial evaluation included
a complete history and physical examination, endoscopy,
and computed tomographic (CT) cervical-thoraco
abdominopelvic scan. Full blood counts, a coagulation
screen, blood chemistry studies, serum lactate dehydroge-
nase levels and plain chest radiography were performed in
all patients. Bone marrow biopsy was performed to evalu-
ate patients who have bone marrow involvement at first
diagnosis. Cheson criteria were used to evaluate the
response in all patients[5,6].
The chemotherapeutic regimen mostly used was CHOP
21 (Cyclophosphamide 750 mg/m2 Intraveinously (IV) at
day1, doxorubicin 50 mg/m2 IV at day1, vincristine 1,4
mg/m2 with a maximum total dose of 2 mg IV at day1 and
prednisone 40 mg/m2/day per os from day 1 to 5). Radio-
therapy (RT) was administered to cover the primary
tumour and all sites of potential contiguous spread, using
a cobalt-60 source in the Waldeyer Ring and in the cervical
lymph nodes areas by 3 fields: two opposed lateral fields
and one anterior. The total dose of RT was 40 Gy delivered
in 2 Gy daily fractions, 5 days per week.
Statistical analysis
Descriptive statistics with 95% confidence interval (CI)
were calculated according to standard procedure. A com-
plete response (CR) was defined as the complete disap-
pearance of all evidence of disease. A partial response (PR)
was defined as a reduction of at least 50% in the initial
tumour volume without the appearance of new lesions.
Disease-free survival (DFS) was measured from the date of
complete response to the date of first relapse. Overall sur-
vival (OS) was measured from the date of diagnosis to the
date of death or last follow-up. Survival curves were con-
structed using the KaplanMeier method. Patients who
failed to achieve complete remission were considered to
have relapsed at time zero when constructing the DFS. The
log-rank test was used to compare survival curves. All tests
were 2-tailed and conducted at a 5% significance level.
Results
Sex ratio was equal to 1.5:1 with a female predominance;
median age was of 52.7 years ranging between 31 and 87
years. 26.9% of the patients had a history of tobacco use.
The most frquent symptoms at first diagnosis were: nasal
obstruction (88.6%), hypoacousia (88.4%), epistaxis
(33.3%), hearing impairment (19,23%) and rhinorrhea
(15.3%). 27% of the patients (7 patients) have systemic
symptoms (Fever, shudder, sweat, and weight loss more
than 5 kg/month). Physical exam showed that clinical cer-
vical lymph nodes were bilateral in 65.3% of patients and
unilateral in 19.2%.
Histology
As shown in Table 1, a variety of histological subtypes
were identified in NNHL, using the WHO classification.
Histological analysis showed follicular lymphoma in 7
cases (26.9%), large B-cell lymphoma in 13 cases (50%),
T-cell lymphoma in 4 cases (15.3%), diffuse mixed B-cell
(3,84%), and extranodal marginal zone B-cell lymphoma
of mucosa-associated lymphoid tissue type malt (3,84%)
[Table 1]. Staging work up was composed of computed
tomography scan of the head and neck, lung, abdomen,
pelvis, and of bone marrow biopsy. Full blood counts, a
coagulation screen, blood chemistry studies, serum lactate
dehydrogenase levels were achieved. According to the Ann
Arbor classification, four patients (15.4%) were at early
stage I, 15 (57.6%) were at stage II, and 3 (11,53%) were
at stage III and 4 (15,38%) at stage IV.
Therapy
Treatment consisted of the combination of chemotherapy
and radiotherapy if localised disease (stage I and II) and
of only chemotherapy if advanced disease (stage III and
IV). The patients that were at stage III and who achievedBMC Ear, Nose and Throat Disorders 2009, 9:11 http://www.biomedcentral.com/1472-6815/9/11
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partial response according to Cheson criteria (up to 50%
after the end of chemotherapy treatment), received com-
plementary treatment with radiotherapy in residual sites
in attempt to achieve complete response. Although a min-
imum of six courses was planned for all patients who
required chemotherapy, the number given varied accord-
ing to the tumour response and patient tolerance. A
median number of 5 (range 2-8) courses was given to
NNHL patients. 73% of patients were managed by 4 to 6
cycles of CHOP21 chemotherapy followed by radiother-
apy. None received prophylactic intrathecal chemother-
apy.
Before radiotherapy, all patients received dental care.
Radiological, clinical, and biological assessment of the
disease was performed after 3, 6 and 8 cycles of chemo-
therapy.
Response
At the end of total treatment, 18 patients (69.2%)
achieved complete response and remained disease free,
while 4 (15.4%) achieved partial response. However, for
four patients (15.4%) the disease was progressing. In this
case also, the 4 patients received a second line chemother-
apy. Local relapse occured in two patients after 6 and 13
months. None of the patients had recurrence in the cen-
tral nervous system, despite its close proximity to the pri-
mary tumour.
Survival
After a median follow-up of 25.9 months (range 2-62), 19
patients were disease free up to their last follow-up and 5
patients did not return for follow up examinations.
Median overall survival at 1 year was equal to 87% (Figure
1). After 18.1 months follow-up, disease free survival rate
at 1 year was equal to 71% (Figure 2). The difference in
term of overall survival and disease free survival between
stage I, II, and III/IV was statistically significant (Log rank
test: P = 0.02 for survival and P = 0.01 for progression free
survival) (figures 3 and 4). Any episode of grade 3-4 tox-
icities neitehr of febrile neutropenia was noted. A radio-
therapy's toxicity (a grade 3 stomatitis) was registred in
one patient, and 30% of patients that received radiother-
apy had xerostomia.
Large B cell subgroup: among this 26 patients, 50% were
large B-Cell lymphoma with a median age of 65,12 years,
and a sex ratio in favor of female sex (2:1). 50% were stage
II, 37,5% stage IV and 12,5% stage I. 37,5% had both
sequential chemo and radiotherapy, and 62,5 had only
chemotherapy because of spread disease. Objective
response rate was about 87,5%(whatever the stage). Sur-
vival rate was 75% at 2 years.
Discussion
Patients having NHL represent a heterogeneous group of
malignant proliferation of the lymphoid system. The ori-
gin of the disease was extra-medullary. This heterogeneity
induces different clinical, pathological, immunological
and cytogenetical presentations. Therefore, the prognosis
is different between the different forms. The incidence of
NHL increased continuously since 1950, particularly the
large B-cell lymphoma sub-type because of HIV epidemy.
Despite the close anatomical relationship between the
various structures in the head and neck region, non-Hodg-
kin's lymphomas arising in these areas are a diverse group
of diseases and may have a different natural history and
response to therapy.
The NHL lymphomas represent the majority of head and
neck lymphomas (65-70%)[7]. The Waldeyer ring was the
site most frequently affected by NHL (ie, the tonsils,
nasopharynx and the base of the tongue)[8]. Few cases of
primary NHL of the nasopharynx were reported in the lit-
erature, and the series published up to now give incom-
plete information on NHL evolution. A number of
authors investigated Head and neck lymphomas and
demonstrated a large predominance of diffuse large B-cell
lymphoma sub type as shown in our study[8-10]
Median age in our series was 52,7 years, most lower than
that reported by Kemp et al[8]. This author reported a
median age of 71 years, which was approximately similar
as reported in others series[10-13]. In our series, 57.9% of
patients were of age lower than 50 years.
Most of our patients were female. The sex ratio
(male:female) was equal to 1:1.5. A similar sex ratio
(0.5:1) was reported by Solomides et al[9]. However,
Table 1: Histological classification and immunophenotype of 26 patients with primary non hodgkin nasopharyngeal lymphomas
Non hodgkin nasopharyngeal lymphoma
(n = 26) (%)
Follicular grade 2 5 (19,23)
Follicular grade 3 2 (7,69)
T cell 4 (15,38)
Diffuse, large B cell 13 (50)
Diffuse, mixed, small and large cell, B 1 (3,84)
Malt 1 (3,84)BMC Ear, Nose and Throat Disorders 2009, 9:11 http://www.biomedcentral.com/1472-6815/9/11
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Kaplan-Meier estimates for overall survival for the entire patients Figure 1
Kaplan-Meier estimates for overall survival for the entire patients.
Kaplan-Meier estimates for disease free survival for the entire patients Figure 2
Kaplan-Meier estimates for disease free survival for the entire patients.BMC Ear, Nose and Throat Disorders 2009, 9:11 http://www.biomedcentral.com/1472-6815/9/11
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Kaplan -Meier curves for the Overall survival by stage (Log-rank test: p = 0.02) Figure 3
Kaplan -Meier curves for the Overall survival by stage (Log-rank test: p = 0.02). No difference between the curves 
for stage I and II: (curves are superimposed), but a significant difference with advanced stages III and IV.
Kaplan-Meier curves for disease free survival according to the NNHL stage Figure 4
Kaplan-Meier curves for disease free survival according to the NNHL stage. (Significant difference between the 
stages: Log-rank test: p = 0.01)BMC Ear, Nose and Throat Disorders 2009, 9:11 http://www.biomedcentral.com/1472-6815/9/11
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Kemp et al., [8] and de Urquhart et al.[13] didn't found
any sex predominance. In contrast, in another series the
authors showed male predominance with a sex ratio equal
to 1.67:1 (25 males and 15 females)[14].
The most important symptoms of Head and Neck NHL
were enlarged masses with or without ulceration and
pain. In our series, the symptoms were nasal obstruction
(88.6%), hypoacousia (88.4%), epistaxis (33.3%) and
rhinorrhea (15.3%). Systemic B symptoms are less com-
monly seen[14,15] as found in our series (in 27% of the
patients).
The present study shows that NNHL is mostly comprised
B-cell disease, as in K. Lei findings [16]. In a study of 54
patients with nasopharyngeal lymphomas, Ye et al. found
an equal incidence of B-cell (51%) and T-cell (49%) lym-
phomas in the nasopharynx [16]. Similarly, in the recent
study of 113 patients reported by Cheung et al. [17], lym-
phoma involving the nasal cavity was mostly of NK/T-cell
or T-cell lineage, while almost half of the lymphomas
involving the nasopharynx were of B-cell lineage.
The management of NNHL low grade NHL at stage I and
II is based on radiotherapy[18]. Other studies showed bet-
ter results which were in favour of the combination of
radiotherapy and chemotherapy as seen in our study[19].
Treatment of localised disease (stage I and II not bulky)
with activity index less than 2 and normal LDH level is
based on CHOP regimen (3 to 4 cycles) plus Rituximab (if
CD20 positive in immunochemistry) followed by radio-
therapy (35-40 Gy in the initial site). In our series, all
patients with early stage NNHL were managed by sequen-
tial radio-chemotherapy, as found in litterature. More
than 80% of patients may be successfully treated (the
sequential treatment induced 82% global survival and
77% survival without disease recurrence). The adverse
events are dominated by hyposialia and hypothyroidia in
one case of thyroid lymphoma, 3,84% in our series. In the
series of patients with stage I and II Head and Neck NHL
reported by Bolla et all, the patients were managed either
with radiotherapy alone (40-55 Gy), with radiotherapy
followed by prophylactic chemotherapy for 6 month, or
with chemotherapy followed by whole brain radiother-
apy, intrathecal methotrexate chemotherapy and adjuvant
chemotherapy. Five years survival was 60% for patient
managed with radiotherapy alone vs. 70% for patients
managed with radio-chemotherapy (p = 0.9%)[20]. In the
case of NNHL at stages III or IV, the treatment was based
on combined chemotherapy. Rituximab-CHOP regimen
is considered as a standard treatment of advanced stage
(Bulky, III and IV with large B-cell lymphoma positive to
CD-20 antigen). The prophylactic strategy was based on
intrathecal methotrexate and systemic high dose meth-
otrexate (up to 3 g/m2), in addition to conventional
chemotherapy (CHOP based chemotherapy) is widely
used given the high risk of central system nervous affec-
tion in case of high grade nasopharynageal lymphoma.
The standard criteria currently used to evaluate the
response to treatment were the criteria established by the
International Working Group in 1999[5]. These criteria
were recently revised by the standardisation of use of PET-
FDG (Positron emission tomography by fluorodextroglu-
cose) in the assessment of the treatment of DLBCL (dif-
fuse large B cell lymphoma) and Hodgkin lymphoma[6].
Prognosis of NNHL is better than nasopharyngeal squa-
mous cell carcinoma's[21]. In the present series we
showed that prognosis of NNHL depended particularly on
the stage of the disease. Prognosis of stage I and II of
NNHL is significantly better than that of stage III and VI
(The probability of survival at 18 months was equal to
100% for stage I and II vs 55% for stage III and 25% for
stage IV, log-rank test: p = 0.02). Other series confirmed
our results and showed better prognosis in case of local-
ised disease and low grade NNHL[15]. Five years survival
was equal to 83% for low grade NHL vs 52% for high
grade NHL, and was equal to 83% for stages I vs 42% for
stage II[22]. Epstein et al reported overall survival of
51.25% and a median survival of de 3.7 years for men and
6.2 years for women[14]. In our series, median overall
survival was 87% at one year and disease free survival was
71% at one year after 25.9 months median follow up. In
our series, survival rate in DLBCL is 75% at two years and
it depends on the stage. Treatement of these patients was
similar than litterature, and even the non-use of rituximab
(non available in our institute in the Nineties), response
rate was satisfactory (87,5%).
Conclusion
Nasopharyngeal non-Hodgkin lymphomas are rare. In
conclusion, lymphomas arising from the nasopharynx
appear to be a particular biological entity. NNHL demon-
strated a higher frequency of B-cell tumours. Novel strate-
gies in the improvement of prognosis should be addressed
in future studies by assessing prognosis factors implicated
in studies. From our results, it could be argued that we
conclude that histological characteristics, principle of
treatment and outcome of moroccan primary NNHL
patients are similar in the present study and in litterature
and can suggest that survival is highly better in early stages
than advanced ones but have to be confirmed.
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